Interesting Cases in HIV Clinical Pharmacology

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > SFGH PHP Grand Rounds > McNicholl > Slides

Interesting Cases in HIV Clinical Pharmacology

Slide Presentation
November 03, 2005
Ian R. McNicholl, PharmD, BCPS (ID)

Click on slide thumbnails to view full-sized image.

Download the entire set of PowerPoint slides

Slide 1.

Interesting Cases in HIV Clinical Pharmacology

Slide 1.

Drug Interaction Primer

Slide 2.

Pharmacokinetic Parameters

Slide 3.

Metabolism

Slide 4.

Cytochrome P450

Slide 5.

Proportion of Drugs Metabolized by CYP450 Enzymes

Slide 6.

Role of P-glycoprotein

Slide 10.

Types of Drug Interactions

Slide 11.

Types of Drug Interactions P450 3A4 Substrates

Slide 12.

P450 3A4 Substrates Recreational Drugs

Slide 13.

Types of Drug Interactions P450 3A4 Induction

Slide 14.

Examples of Induction

Slide 15.

Types of Drug Interactions P450 3A4 Inhibition

Slide 16.

Sildenafil and PI Interactions

Slide 17.

PDE5 Inhibitor Comparison

Slide 18.

Examples of Inhibition

Slide 19.

Slide 20

Slide 20.

Case 1

Slide 21.

Case 1

Slide 22.

FDA-Approved H. pylori Treatment Regimens

Slide 23.

Proton Pump Inhibitor Comparison

Slide 24.

Results ATV and Omeprazole

Slide 25.

H2-Blocker Comparison

Slide 27.

Pharmacokinetic Summary ATV and famotidine

Slide 29.

Amprenavir PK

Slide 31.

Effects of Acid Reduction on PI Pharmacokinetics

Slide 32.

Case 2

Slide 33.

Case 2

Slide 34.

Case 2

Slide 35.

Rosuvastatin (Crestor)

Slide 36.

Rosuvastatin

Slide 37.

Case 3

Slide 38.

Case 3

Slide 39.

ACTG A5047 Statin Interaction with PIs

Slide 40.

Anti-lipidemics and PIs

Slide 41.

Major Risk Factors That Modify LDL Goals

Slide 42.

CVD Risk Factors

Slide 43.

LDL Goals for Therapeutic Lifestyle Changes and Drug Therapy

Slide 44.

Drug Therapy

Slide 45.

Statin Comparison, Efficacy and Dosing

Slide 46.

Case 3

Slide 47.

PROVE IT TIMI 22 (2-Year Trial)

Slide 48.

Clinical Relevance of Achieved LDL-C and Achieved CRP after Treatment with Statin Therapy: PROVE IT TIMI 22

Slide 50.

Case 3

Slide 52.

Ezetimibe (Zetia)

Slide 53.

Ezetimibe Efficacy as Add-On Therapy

Slide 54.

Investigational Agents

Slide 55.

Nucleoside/tide RTIs

Slide 56.

Non-nucleoside RTIs

Slide 57.

Protease inhibitors

Slide 58.

TPV/r Drug Interactions

Slide 60.

Classes of Entry Inhibitors

Slide 61.

CCR5 Inhibitors in Development

Slide 62.

1 Minute Counsel

Slide 63.

1 Minute Counsel

Slide 64.

Summary

Slide 65.

Slide 66

Slide 66.

Questions?

Slide 68.